Suppr超能文献

接受每日血液透析的终末期肾病儿童的生长情况

Growth of children with end-stage renal disease undergoing daily hemodialysis.

作者信息

de Camargo Maria Fernanda Carvalho, Henriques Cristina Lucia, Vieira Simone, Komi Shirlei, Leão Eliseth Ribeiro, Nogueira Paulo Cesar Koch

机构信息

Dialysis and Pediatric Kidney Transplants, Hospital Samaritano de São Paulo, Sao Paulo, Sao Paulo, Brazil.

出版信息

Pediatr Nephrol. 2014 Mar;29(3):439-44. doi: 10.1007/s00467-013-2676-4. Epub 2013 Nov 20.

Abstract

BACKGROUND

The aim of this report is to describe the effect of daily hemodialysis on the growth of children with end-stage renal disease (ESRD).

METHODS

We performed a prospective, observational study on 24 children with ESRD undergoing daily hemodialysis (DHD). The control group comprised 26 children on concurrent conventional hemodialysis (CHD), and the follow-up for both groups was 9.3 ± 3.0 months. No patient received growth hormone (GH) therapy.

RESULTS

At the onset of the study, the height-for-age Z-score was -2.12 ± 1.54 in the CHD group and -2.84 ± 2.27 in the DHD group (p = 0.313). Assuming an increase of 0.5 standard deviation scores (SDS) of the height-for-age parameter as an improvement of growth, there were 33 % of patients in the DHD group and 8 % in the CHD group (p = 0.035). The cumulative probability of gain in height for age at 12 months was 40 % in the DHD group versus 15 % in the CHD group (p = 0.047). Also, 98 % of patients in the DHD group had an adequate total caloric intake, whereas 38 % in the CHD group reached this goal (p < 0.001). No patient left the study due to intensification of the dialysis modality.

CONCLUSIONS

Our data show that the DHD favored a 0.5 SDS height gain in a third of patients without GH treatment. Dialysis intensification was not a cause for treatment dropouts, and DHD should be considered as a treatment for selected cases, especially small children.

摘要

背景

本报告旨在描述每日血液透析对终末期肾病(ESRD)儿童生长发育的影响。

方法

我们对24例接受每日血液透析(DHD)的ESRD儿童进行了一项前瞻性观察研究。对照组包括26例同时接受常规血液透析(CHD)的儿童,两组的随访时间为9.3±3.0个月。没有患者接受生长激素(GH)治疗。

结果

在研究开始时,CHD组的年龄别身高Z评分是-2.12±1.54,DHD组是-2.84±2.27(p=0.313)。假设年龄别身高参数增加0.5个标准差评分(SDS)为生长改善,DHD组有33%的患者达到这一标准,CHD组为8%(p=0.035)。DHD组12个月时年龄别身高增加的累积概率为40%,而CHD组为15%(p=0.047)。此外,DHD组98%的患者总热量摄入充足,而CHD组只有38%的患者达到这一目标(p<0.001)。没有患者因透析方式强化而退出研究。

结论

我们的数据表明,在未接受GH治疗的患者中,三分之一的患者通过DHD实现了身高增加0.5 SDS。透析强化不是导致治疗退出的原因,DHD应被视为特定病例的一种治疗方法,尤其是年幼儿童。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验